Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Recro PharmaPDS BiotechnologyNeuroBo PharmaceuticalsCellectar BiosciencesAdvaxis
SymbolNASDAQ:REPHNASDAQ:PDSBNASDAQ:NRBONASDAQ:CLRBNASDAQ:ADXS
Price Information
Current Price$2.76$5.39$3.23$1.42$0.47
52 Week RangeBuyBuyBuyBuyN/A
MarketRank™
Overall Score1.81.51.71.40.6
Analysis Score3.53.53.53.50.0
Community Score2.63.33.32.72.4
Dividend Score0.00.00.00.00.0
Ownership Score0.80.00.80.00.0
Earnings & Valuation Score1.90.60.60.60.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyN/A
Consensus Price Target$12.00$7.62$16.00$3.67N/A
% Upside from Price Target334.78% upside41.37% upside395.36% upside158.22% upsideN/A
Trade Information
Market Cap$85.60 million$119.99 million$63.54 million$71.72 million$56.46 million
Beta1.252.70.691.673.18
Average Volume627,5471,511,107415,8091,795,93612,103,001
Sales & Book Value
Annual Revenue$99.22 millionN/AN/AN/A$20.88 million
Price / Sales0.86N/AN/AN/A2.70
Cashflow$0.54 per shareN/AN/AN/AN/A
Price / Cash5.10N/AN/AN/AN/A
Book Value($0.30) per share$2.22 per share$0.79 per share$0.84 per share$2.30 per share
Price / Book-9.20N/AN/AN/A0.20
Profitability
Net Income$-18,630,000.00$-7,000,000.00$-21,310,000.00$-14,090,000.00$-16,610,000.00
EPS$0.20($3.57)($4.08)($1.84)N/A
Trailing P/E Ratio13.80N/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-34.14%N/AN/AN/A-13,144.62%
Return on Equity (ROE)N/A-67.41%-224.41%-129.44%-81.49%
Return on Assets (ROA)-18.97%-57.74%-171.64%-90.76%-66.32%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/A0.01%N/A
Current Ratio3.95%11.67%3.57%5.01%8.40%
Quick Ratio3.17%11.67%3.57%5.01%8.40%
Ownership Information
Institutional Ownership Percentage56.34%14.80%4.50%12.67%10.50%
Insider Ownership Percentage23.10%17.78%56.10%5.27%0.26%
Miscellaneous
Employees18515121117
Shares Outstanding31.01 million22.26 million19.67 million50.50 million120.38 million
Next Earnings Date5/10/2021 (Estimated)5/12/2021 (Estimated)5/19/2021 (Estimated)5/6/2021 (Estimated)6/10/2021 (Estimated)
OptionableOptionableNot OptionableNot OptionableNot OptionableOptionable
SourceHeadline
Global Targeted Drug Delivery Device Market 2021 Growth Rate: 4D Molecular Therapeutics, AbbVie, Abeona Therapeutics, Advaxis - Valley Bugler NewspaperGlobal Targeted Drug Delivery Device Market 2021 Growth Rate: 4D Molecular Therapeutics, AbbVie, Abeona Therapeutics, Advaxis - Valley Bugler Newspaper
valleybugler.com - April 16 at 9:56 AM
Insights on Cancer Targeted Therapy Market: Facts, Figures and Trends 2020-2026 by Advaxis , Bind Therapeutics , Boehringer Ingelheim , Bristol Mayer Squibb , Celldex Therapeutics , Dendreon Corporation , and more | Affluence - Los Hijos de la MalincheInsights on Cancer Targeted Therapy Market: Facts, Figures and Trends 2020-2026 by Advaxis , Bind Therapeutics , Boehringer Ingelheim , Bristol Mayer Squibb , Celldex Therapeutics , Dendreon Corporation , and more | Affluence - Los Hijos de la Malinche
loshijosdelamalinche.com - April 14 at 10:42 AM
Advaxis, Inc. (ADXS) has great growth outlook for 2021Advaxis, Inc. (ADXS) has great growth outlook for 2021
marketingsentinel.com - April 13 at 9:37 AM
Is This The Best Time To Buy Advaxis, Inc. (NASDAQ:ADXS) Stock?Is This The Best Time To Buy Advaxis, Inc. (NASDAQ:ADXS) Stock?
stocksregister.com - April 13 at 9:37 AM
Form 8-K Advaxis, Inc. For: Apr 12 - StreetInsider.comForm 8-K Advaxis, Inc. For: Apr 12 - StreetInsider.com
streetinsider.com - April 12 at 6:36 PM
Advaxis, Inc. Announces $20 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Yahoo FinanceAdvaxis, Inc. Announces $20 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Yahoo Finance
finance.yahoo.com - April 12 at 6:36 PM
Advaxis, Inc. Announces $20 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewswireAdvaxis, Inc. Announces $20 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewswire
globenewswire.com - April 12 at 1:35 PM
Advaxis, Inc. Announces $20 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesAdvaxis, Inc. Announces $20 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
finance.yahoo.com - April 12 at 1:35 PM
Advaxis Presents Translational Biomarker Data from Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial at the American Associated for Cancer Research (AACR) 2021 Annual Meeting - GlobeNewswireAdvaxis Presents Translational Biomarker Data from Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial at the American Associated for Cancer Research (AACR) 2021 Annual Meeting - GlobeNewswire
globenewswire.com - April 10 at 1:30 PM
Advaxis Presents Translational Biomarker Data from Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial at the American Associated for Cancer Research (AACR) 2021 Annual MeetingAdvaxis Presents Translational Biomarker Data from Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial at the American Associated for Cancer Research (AACR) 2021 Annual Meeting
finance.yahoo.com - April 10 at 1:30 PM
Advaxis (NASDAQ:ADXS) Share Price Passes Above Two Hundred Day Moving Average of $0.58Advaxis (NASDAQ:ADXS) Share Price Passes Above Two Hundred Day Moving Average of $0.58
americanbankingnews.com - April 8 at 2:32 AM
Why is Advaxis (ADXS) Weak Despite Positive Developments? – Own Snap - Own SnapWhy is Advaxis (ADXS) Weak Despite Positive Developments? – Own Snap - Own Snap
ownsnap.com - April 6 at 9:49 AM
Other news to note for April 5, 2021 | 2021-04-05 - BioWorld OnlineOther news to note for April 5, 2021 | 2021-04-05 - BioWorld Online
bioworld.com - April 5 at 6:02 PM
Advaxis to fund earl-stage ADXS-504 study for prostate cancer - Seeking AlphaAdvaxis to fund earl-stage ADXS-504 study for prostate cancer - Seeking Alpha
seekingalpha.com - April 5 at 6:02 PM
Advaxis Announces Agreement with Columbia University Irving Medical Center to Fund Phase 1 Study of ADXS-504 for the Treatment of Early Prostate Cancer - Yahoo FinanceAdvaxis Announces Agreement with Columbia University Irving Medical Center to Fund Phase 1 Study of ADXS-504 for the Treatment of Early Prostate Cancer - Yahoo Finance
finance.yahoo.com - April 5 at 6:02 PM
Advaxis Announces Agreement with Columbia University Irving Medical Center to Fund Phase 1 Study of ADXS-504 for the Treatment of Early Prostate Cancer - GlobeNewswireAdvaxis Announces Agreement with Columbia University Irving Medical Center to Fund Phase 1 Study of ADXS-504 for the Treatment of Early Prostate Cancer - GlobeNewswire
globenewswire.com - April 5 at 1:02 PM
Advaxis Announces Agreement with Columbia University Irving Medical Center to Fund Phase 1 Study of ADXS-504 for the Treatment of Early Prostate CancerAdvaxis Announces Agreement with Columbia University Irving Medical Center to Fund Phase 1 Study of ADXS-504 for the Treatment of Early Prostate Cancer
finance.yahoo.com - April 5 at 1:02 PM
Here is all you need to know about Advaxis, Inc (ADXS) stock - Park TelegraphHere is all you need to know about Advaxis, Inc (ADXS) stock - Park Telegraph
parktelegraph.com - April 1 at 12:54 PM
Cancer Vaccines Market Segmentation by Type, Application, Region and Key Players Analysis Upto 2028: Advaxis Inc., Dynavax Technologies Corporation, Amgen Inc., Generex Biotechnology Corporation, Immunocellular Therapeutics, Ltd, GlaxoSmithKline plc., Merck & Co., etc. - Jumbo NewsCancer Vaccines Market Segmentation by Type, Application, Region and Key Players Analysis Upto 2028: Advaxis Inc., Dynavax Technologies Corporation, Amgen Inc., Generex Biotechnology Corporation, Immunocellular Therapeutics, Ltd, GlaxoSmithKline plc., Merck & Co., etc. - Jumbo News
jumbonews.co.uk - April 1 at 7:54 AM
Neoantigen Targeted Therapies Market Incredible Future (2021:2027) | Business Growth Scenario Till 2027 | Achilles Therapeutics, Advaxis, Inc., Frame Cancer Therapeutics, Genocea Biosciences, Inc., Gradalis & More - FLA NewsNeoantigen Targeted Therapies Market Incredible Future (2021:2027) | Business Growth Scenario Till 2027 | Achilles Therapeutics, Advaxis, Inc., Frame Cancer Therapeutics, Genocea Biosciences, Inc., Gradalis & More - FLA News
flanewsonline.com - March 30 at 2:35 PM
Is Advaxis, Inc. (NASDAQ:ADXS) Stock Ready for a Higher Run in its Share Price?Is Advaxis, Inc. (NASDAQ:ADXS) Stock Ready for a Higher Run in its Share Price?
marketingsentinel.com - March 29 at 6:32 PM
Global Anal and Colorectal Cancer Market 2025: Abbott Diagnostics, Advaxis, Alere, Amgen, Atara Biotherapeutics, Bayer, Metabiomics, Beckman Coulter, BeiGene, Boehringer Ingelheim, Clinical Genomics, EDP Biotech, Eli Lilly, Epigenomics, Exact Sciences, Genomictree, Immunovaccine, ISA Pharmaceuticals, Merck etc. - The Market EagleGlobal Anal and Colorectal Cancer Market 2025: Abbott Diagnostics, Advaxis, Alere, Amgen, Atara Biotherapeutics, Bayer, Metabiomics, Beckman Coulter, BeiGene, Boehringer Ingelheim, Clinical Genomics, EDP Biotech, Eli Lilly, Epigenomics, Exact Sciences, Genomictree, Immunovaccine, ISA Pharmaceuticals, Merck etc. - The Market Eagle
themarketeagle.com - March 27 at 7:23 PM
Analysts Say You Should Go Buying Advaxis, Inc. (NASDAQ:ADXS)Analysts Say You Should Go Buying Advaxis, Inc. (NASDAQ:ADXS)
stocksregister.com - March 27 at 4:22 AM
Market Analysts see Advaxis Inc. [ADXS] gaining to $20. Time to buy?Market Analysts see Advaxis Inc. [ADXS] gaining to $20. Time to buy?
dbtnews.com - March 26 at 8:20 AM
Anal and Colorectal Cancer Market Report 2025 : Abbott Diagnostics, Advaxis, Alere, Amgen, Atara Biotherapeutics, Bayer, Metabiomics, Beckman Coulter, BeiGene, Boehringer Ingelheim, Clinical Genomics, EDP Biotech, Eli Lilly, Epigenomics, Exact Sciences, Genomictree, Immunovaccine, ISA Pharmaceuticals, Merck - The Market EagleAnal and Colorectal Cancer Market Report 2025 : Abbott Diagnostics, Advaxis, Alere, Amgen, Atara Biotherapeutics, Bayer, Metabiomics, Beckman Coulter, BeiGene, Boehringer Ingelheim, Clinical Genomics, EDP Biotech, Eli Lilly, Epigenomics, Exact Sciences, Genomictree, Immunovaccine, ISA Pharmaceuticals, Merck - The Market Eagle
themarketeagle.com - March 25 at 8:24 PM
DateCompanyBrokerageAction
1/4/2021Recro PharmaCraig HallumInitiated Coverage
5/12/2020Recro PharmaOppenheimerLower Price Target
3/5/2020Recro PharmaStephensLower Price Target
3/25/2019Recro PharmaRoth CapitalReiterated Rating
1/31/2019Recro PharmaJanney Montgomery ScottReiterated Rating
11/8/2018Recro PharmaPiper Jaffray CompaniesSet Price Target
4/19/2018Recro PharmaBerenberg BankInitiated Coverage
4/10/2021PDS BiotechnologyChardan CapitalReiterated Rating
3/25/2021PDS BiotechnologyHC WainwrightBoost Price Target
10/6/2020PDS BiotechnologyNoble FinancialReiterated Rating
7/28/2020PDS BiotechnologyAlliance Global PartnersBoost Price Target
2/18/2020NeuroBo PharmaceuticalsLADENBURG THALM/SH SHInitiated Coverage
6/23/2020Cellectar BiosciencesMaxim GroupInitiated Coverage
7/29/2019Cellectar BiosciencesBrookline Capital ManagementInitiated Coverage
6/13/2018AdvaxisJefferies Financial GroupDowngrade
(Data available from 4/17/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.